A California-based veterinary medicine company plans to spend $3.75 million to purchase manufacturing facilities near St. Joseph, Mo., where it will produce an injectable treatment for pyrexia, or fevers, in horses.
Kindred Biosciences announced Monday the purchase of the eight-acre plot of land in Elwood, Kan., that includes two buildings totaling 180,000 square feet. It was formerly owned by Boehringer Ingelheim and by Strategic Veterinary Pharmaceuticals.
The KC Animal Health Corridor, a collective of 300 companies from Manhattan, Kan., to Columbia, Mo., assisted Kindred Biosciences with its site search.
“KindredBio is a welcome addition to the Corridor as they kick off commercialization of the company’s first product offerings and create new jobs in our region,” Kimberly Young, the president of the KC Animal Health Corridor, said in a written statement. “More and more, the growth of the animal health industry in the Corridor is reliant on young companies taking innovative products and services from the lab to the marketplace.”
The company expects to close on the purchase within 30 days but has not provided any estimates of how many jobs might be at the plant.